A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk

Wang, Tianyi; Cai, Hui; Wang, Zheng; Michel, Angelika; Pawlita, Michael; Milne, Ginger L.; Xiang, Yong‐Bing; Gao, Yu‐Tang; Li, Honglan; Rothman, Nathaniel; Lan, Qing; Epplein, Meira

doi:10.1093/cid/cix106

Cited by 22 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since measurement of the urinary PGE 2 metabolite PGE-M is an effective way to quantify systemic PGE 2 production in vivo, much work has been done to evaluate whether urinary PGE-M levels could serve as a promising biomarker for predicting cancer risk and prognosis. Emerging epidemiologic evidence and a phase II biomarker study showed that urinary PGE-M levels were associated with an increased risk of developing CRC and GC (49)(50)(51)(52)(53). These results suggest that urinary PGE-M could be used as a biomarker for predicting gastrointestinal cancer risk and prognosis.…”

Section: Prostanoids and Gastrointestinal Cancermentioning

confidence: 89%

Role of prostanoids in gastrointestinal cancer

Wang¹,

DuBois²

2018

Journal of Clinical Investigation

127

124

View full text Add to dashboard Cite

Chronic inflammation is a risk factor for gastrointestinal cancer and other diseases. Most studies have focused on cytokines and chemokines as mediators connecting chronic inflammation to cancer, whereas the involvement of lipid mediators, including prostanoids, has not been extensively investigated. Prostanoids are among the earliest signaling molecules released in response to inflammation. Multiple lines of evidence suggest that prostanoids are involved in gastrointestinal cancer. In this Review, we discuss how prostanoids impact gastrointestinal cancer development. In particular, we highlight recent advances in our understanding of how prostaglandin E2 induces the immunosuppressive microenvironment in gastrointestinal cancers.

show abstract

Section: Prostanoids and Gastrointestinal Cancermentioning

confidence: 89%

Role of prostanoids in gastrointestinal cancer

Wang¹,

DuBois²

2018

Journal of Clinical Investigation

127

124

View full text Add to dashboard Cite

show abstract

“…A comprehensive review on the role of prostanoids in gastrointestinal cancer was recently published (Wang and DuBois 2018). Among prostanoids, PGE2 is the most abundant in human GC (Uefuji et al 2000), and the measurement of its metabolite (PGE-M) levels in urine has shown PGE-M could be used as a biomarker for predicting GC risk and prognosis (Wang et al 2017).…”

Section: Anti-cancer Strategies Targeting the Pro-inflammatory Mediatmentioning

confidence: 99%

Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy

Piazuelo

Riechelmann

Wilson

et al. 2019

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

The connection between inflammation and cancer was initially recognized by Rudolf Virchow in the nineteenth century. During the last decades, a large body of evidence has provided support to his hypothesis, and now inflammation is recognized as one of the hallmarks of cancer, both in the etiopathogenesis and in ongoing tumor growth. Infection with the pathogen Helicobacter pylori is the primary causal factor in 90% of gastric cancer cases. As we increase our understanding of how chronic inflammation develops in the stomach and contributes to carcinogenesis, there is increasing interest in targeting cancer-promoting inflammation as a strategy to treat gastric cancer. Moreover, once cancer develops and anti-cancer immune responses are suppressed, there is evidence of a substantial shift in the microenvironment and new targets for immune therapy emerge. In this chapter, we provide insight into inflammation-related factors, including T lymphocytes, macrophages, pro-inflammatory chemokines and cytokines, which promote H. pylori-associated gastric cancer initiation and growth. While intervening with chronic inflammation is not a new practice in rheumatology or gastroenterology, this approach has not been fully explored for its potential to prevent carcinogenesis or to contribute to the treatment of gastric cancer. This review highlights current and possible strategies for therapeutic intervention including: i) targeting pro-inflammatory mediators, ii) targeting growth factors and pathways involved in angiogenesis in the gastric tumor microenvironment, and iii) enhancing anti-tumor immunity. In addition, we highlight a significant number of clinical trials and discuss the importance of individual tumor characterization towards offering personalized immune-related therapy.

show abstract

“…Chronic inflammation has been linked to the development of some tumors [ 162 , 163 , 164 ], and it is known that diseases such as pancreatitis [ 165 ], hepatic steatosis or Crohn’s disease [ 166 ], which present chronic inflammation, significantly increase the risk of cancer. This direct relationship with cancer development is also observed in infectious diseases that produce inflammation, such as hepatitis [ 167 , 168 ] or stomach infection by Helicobacter pylori [ 169 , 170 , 171 ].…”

Section: Breast Cancer Signatures and Polyphenolsmentioning

confidence: 87%

Polyphenols as Promising Drugs against Main Breast Cancer Signatures

et al. 2017

View full text Add to dashboard Cite

Breast cancer is one of the most common neoplasms worldwide, and in spite of clinical and pharmacological advances, it is still a clinical problem, causing morbidity and mortality. On the one hand, breast cancer shares with other neoplasms some molecular signatures such as an imbalanced redox state, cell cycle alterations, increased proliferation and an inflammatory status. On the other hand, breast cancer shows differential molecular subtypes that determine its prognosis and treatment. These are characterized mainly by hormone receptors especially estrogen receptors (ERs) and epidermal growth factor receptor 2 (HER2). Tumors with none of these receptors are classified as triple negative breast cancer (TNBC) and are associated with a worse prognosis. The success of treatments partially depends on their specificity and the adequate molecular classification of tumors. New advances in anticancer drug discovery using natural compounds have been made in the last few decades, and polyphenols have emerged as promising molecules. They may act on various molecular targets because of their promiscuous behavior, presenting several physiological effects, some of which confer antitumor activity. This review analyzes the accumulated evidence of the antitumor effects of plant polyphenols on breast cancer, with special attention to their activity on ERs and HER2 targets and also covering different aspects such as redox balance, uncontrolled proliferation and chronic inflammation.

show abstract

A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk

Cited by 22 publications

References 37 publications

Role of prostanoids in gastrointestinal cancer

Role of prostanoids in gastrointestinal cancer

Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy

Polyphenols as Promising Drugs against Main Breast Cancer Signatures

Contact Info

Product

Resources

About